Table 2.
TEASs (all causality)
| Adverse event | Elranatamab SC monotherapy (n = 55) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total | |
| Hematologic | |||||
| Neutropenia | 0 | 2 (3.6) | 14 (25.5) | 25 (45.5) | 41 (74.5) |
| Anemia | 1 (1.8) | 8 (14.5) | 28 (50.9) | 0 | 37 (67.3) |
| Lymphopenia | 0 | 1 (1.8) | 3 (5.5) | 25 (45.5) | 29 (52.7) |
| Thrombocytopenia | 6 (10.9) | 6 (10.9) | 6 (10.9) | 10 (18.2) | 28 (50.9) |
| Non-hematologic | |||||
| CRSa | 28 (50.9) | 20 (36.4) | 0 | 0 | 48 (87.3) |
| Injection site reaction | 27 (49.1) | 4 (7.3) | 0 | 0 | 31 (56.4) |
| Fatigue | 7 (12.7) | 12 (21.8) | 4 (7.3) | 0 | 23 (41.8) |
| Diarrhea | 12 (21.8) | 8 (14.5) | 2 (3.6) | 0 | 22 (40.0) |
| Dry skin | 18 (32.7) | 2 (3.6) | 0 | 0 | 20 (36.4) |
| Hypophosphatemia | 0 | 6 (10.9) | 13 (23.6) | 1 (1.8) | 20 (36.4) |
| Decreased appetite | 11 (20.0) | 7 (12.7) | 1 (1.8) | 0 | 19 (34.5) |
| Nausea | 6 (10.9) | 10 (18.2) | 3 (5.5) | 0 | 19 (34.5) |
Values are n (%). Data cutoff was 30 September 2022. Any grade TEAEs reported in more than 33.3% of patients. Grading of TEAEs was based on NCI CTCAE version 4.03, except for CRS. Grading of CRS was based on Lee et al.13.
aTwenty patients received no priming or premedication; 20 patients received priming only; and 15 patients received priming plus premedication. In the group that received priming plus premedication, the overall incidence of CRS was 67% and limited to grade 1 (33%) and grade 2 (33%), with seven (47%) patients receiving tocilizumab.
SC, subcutaneous.